Recurrent Gastric Cancer


Herceptin® Approved for HER2-positive Metastatic Stomach Cancer (11-2-2010)

The U.S. Food and Drug Administration (FDA) has expanded the approval of Herceptin® (trastuzumab) to include the initial treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction in combination with chemotherapy.[1] Herceptin... Continue Reading

Clinical Trial for Advanced Gastric Cancer Now Enrolling Patients (07-16-2010)

Gastric cancer forms in the tissues and lining of the stomach. Current treatment options include surgery, chemotherapy, and radiation. The current standard of care for metastatic gastric cancer is systemic therapy. Research is ongoing to determine which... Continue Reading

Herceptin® Improves Survival with HER2-positive Gastric Cancer (06-2-2009)

Herceptin® Improves Survival with HER2-positive Gastric Cancer According to the results of a Phase III clinical trial presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO), treatment with a combination of chemotherapy... Continue Reading

« Previous Page